Otilonium Bromide: Precision Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (SKU B1607) is a solid, high-purity antimuscarinic agent (≥98%) that selectively inhibits acetylcholine receptors (AChR), enabling precise control of cholinergic signaling in neuroscience and gastrointestinal models (APExBIO). It exhibits superior solubility in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL), facilitating versatile experimental design. It is not intended for diagnostic or clinical use but is optimized for research applications investigating smooth muscle contraction and motility disorders. Reliable storage at -20°C and recommendations for short-term solution use preserve its efficacy. These properties make Otilonium Bromide a benchmark reagent for receptor modulation and antispasmodic pharmacology in the laboratory (Vijayan et al., 2021).

Biological Rationale

Cholinergic signaling pathways underpin essential processes in the central and peripheral nervous systems (Vijayan et al., 2021). Acetylcholine functions as a neurotransmitter mediating smooth muscle contraction, especially in the gastrointestinal tract. Overactivity of muscarinic receptors is implicated in gastrointestinal motility disorders, including irritable bowel syndrome (IBS) and functional bowel diseases. Selective blockade of muscarinic acetylcholine receptors enables targeted investigation of these pathways. Otilonium Bromide provides a tool for dissecting receptor-mediated physiological responses without systemic cholinergic suppression. Its use extends to modeling smooth muscle spasm, evaluating antispasmodic pharmacology, and probing receptor dynamics in both in vitro and ex vivo systems.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (AChR), specifically targeting M2 and M3 subtypes (APExBIO). By binding to these receptors, it prevents acetylcholine from activating downstream signaling cascades. This inhibition suppresses smooth muscle contraction, leading to an antispasmodic effect. The compound's molecular formula is C29H43BrN2O4, and it has a molecular weight of 563.57 g/mol. Its selectivity allows for the discrimination of muscarinic versus nicotinic receptor responses in experimental models. The reversible nature of its binding supports temporal control in functional assays, making it suitable for acute pharmacological studies.

Evidence & Benchmarks

• Otilonium Bromide displays high water solubility (≥55.8 mg/mL at 20°C), supporting preparation of concentrated stock solutions for in vitro assays (APExBIO).
• It demonstrates ≥98% purity, minimizing confounding off-target effects in receptor modulation experiments (APExBIO).
• Antimuscarinic inhibition of smooth muscle contraction has been directly correlated with Otilonium Bromide's blockade of muscarinic AChR in controlled tissue studies (see Table 2 in Vijayan et al., 2021).
• Solutions remain stable at -20°C, but are recommended for short-term use (<2 weeks) to maintain inhibitory potency (manufacturer protocol: APExBIO).
• Otilonium Bromide is not indicated for clinical, diagnostic, or in vivo therapeutic use (see product restrictions: APExBIO).

Applications, Limits & Misconceptions

Otilonium Bromide's primary application is in the selective inhibition of muscarinic AChR-mediated responses in neuroscience and gastrointestinal models. Its antispasmodic properties allow researchers to probe smooth muscle contraction mechanisms and test pharmacological hypotheses related to cholinergic signaling. The compound is highly valued in cell viability, proliferation, and cytotoxicity assays where selective receptor modulation is required (see MeropenemCAS review). This article clarifies the precise concentration ranges and workflow integration strategies not covered in prior scenario-driven guides.

• Supports reproducible modulation of cholinergic signaling pathways in vitro and ex vivo.
• Facilitates modeling of gastrointestinal motility disorders without systemic effects.
• Enables benchmarking of receptor antagonist selectivity and potency.

Compared to prior reviews on antimuscarinic agent workflow optimization (AT7519Hydrochloride.com), this article extends practical advice by emphasizing the solubility parameters and solution stability conditions required for high-throughput screening.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: Otilonium Bromide is restricted to research use; it is not approved for clinical applications (APExBIO).
• Limited to muscarinic receptors: It does not inhibit nicotinic acetylcholine receptors or non-cholinergic pathways.
• Solution stability: Solutions degrade upon repeated freeze-thaw cycles; always prepare fresh for each experiment.
• Not suitable for long-term in vivo studies: Pharmacokinetics and systemic safety have not been established for animal or human use.
• Potential for off-target effects at excessive concentrations: Use within recommended ranges to ensure receptor selectivity.

Workflow Integration & Parameters

For highest reproducibility, dissolve Otilonium Bromide in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), or ethanol (≥91 mg/mL) under sterile conditions. Filter stock solutions using 0.22 µm filters prior to cell culture or tissue application. Store at -20°C and avoid repeated freeze-thaw cycles. Prepare working dilutions immediately before use, and discard unused portions after each experiment. For cell-based assays, typical working concentrations range from 0.1 µM to 100 µM, depending on model sensitivity and endpoint measurements. Refer to APExBIO protocols for specific dosing guidance (Otilonium Bromide workflow).

Integration with viability and cytotoxicity assays is streamlined due to its high solubility and minimal cytotoxicity at recommended concentrations. For detailed troubleshooting and scenario-based optimization, see guidance in recent comparative reviews (Corticostatin.com), which this article updates by specifying validated solubility and storage conditions.

Conclusion & Outlook

Otilonium Bromide (B1607) from APExBIO serves as a reference antimuscarinic agent for research on cholinergic signaling and smooth muscle function. Its high purity, solubility, and selectivity underpin robust experimental design. Future developments may include expanded structure-activity analyses and integration with high-throughput screening platforms. Researchers should remain attentive to solution stability and application-specific parameters to ensure optimal data quality. This article consolidates current best practices, extending previous guidance with new quantitative benchmarks for solution preparation and storage in the laboratory environment.